相似文献
1
Preventing Infection by Human Cytomegalovirus.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S123-S127. doi: 10.1093/infdis/jiz448.
2
The Status of Vaccine Development Against the Human Cytomegalovirus.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
3
Vaccination against the human cytomegalovirus.
Vaccine. 2019 Nov 28;37(50):7437-7442. doi: 10.1016/j.vaccine.2018.02.089. Epub 2018 Apr 3.
4
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
EBioMedicine. 2019 Dec;50:45-54. doi: 10.1016/j.ebiom.2019.11.005. Epub 2019 Nov 15.
5
The history of vaccination against cytomegalovirus.
Med Microbiol Immunol. 2015 Jun;204(3):247-54. doi: 10.1007/s00430-015-0388-z. Epub 2015 Mar 20.
6
Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S103-S108. doi: 10.1093/infdis/jiz523.
7
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.
8
A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00747-19. Print 2019 Dec 1.
9
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.
10
Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
Vaccine. 2018 Mar 14;36(12):1689-1699. doi: 10.1016/j.vaccine.2018.01.029. Epub 2018 Feb 15.
引用本文的文献
1
A vaccine against cytomegalovirus: how close are we?
J Clin Invest. 2025 Jan 2;135(1):e182317. doi: 10.1172/JCI182317.
2
Spatial kinetics and immune control of murine cytomegalovirus infection in the salivary glands.
PLoS Comput Biol. 2024 Aug 16;20(8):e1011940. doi: 10.1371/journal.pcbi.1011940. eCollection 2024 Aug.
3
Re-Evaluating Human Cytomegalovirus Vaccine Design: Prediction of T Cell Epitopes.
Vaccines (Basel). 2023 Oct 24;11(11):1629. doi: 10.3390/vaccines11111629.
4
Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.
Infect Dis Clin North Am. 2023 Nov 20. doi: 10.1016/j.idc.2023.10.001.
5
Targeted Protein-Specific Multi-Epitope-Based Vaccine Designing against Human Cytomegalovirus by Using Immunoinformatics Approaches.
Vaccines (Basel). 2023 Jan 17;11(2):203. doi: 10.3390/vaccines11020203.
6
An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine.
Vaccines (Basel). 2022 Aug 16;10(8):1326. doi: 10.3390/vaccines10081326.
7
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.
Annu Rev Virol. 2022 Sep 29;9(1):491-520. doi: 10.1146/annurev-virology-100220-010653. Epub 2022 Jun 15.
8
Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.
PLoS One. 2022 Mar 21;17(3):e0265424. doi: 10.1371/journal.pone.0265424. eCollection 2022.
9
Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.
PLoS Pathog. 2021 Dec 9;17(12):e1010061. doi: 10.1371/journal.ppat.1010061. eCollection 2021 Dec.
10
Evasion of the Host Immune Response by Betaherpesviruses.
Int J Mol Sci. 2021 Jul 13;22(14):7503. doi: 10.3390/ijms22147503.
本文引用的文献
1
The Status of Vaccine Development Against the Human Cytomegalovirus.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
2
Review of Mathematical Models of Vaccination for Preventing Congenital Cytomegalovirus Infection.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S86-S93. doi: 10.1093/infdis/jiz402.
3
Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.126047.
4
HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission.
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3728-3733. doi: 10.1073/pnas.1814835116. Epub 2019 Feb 7.
5
Pathogen at the Gates: Human Cytomegalovirus Entry and Cell Tropism.
Viruses. 2018 Dec 11;10(12):704. doi: 10.3390/v10120704.
6
Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Vaccine. 2018 Sep 5;36(37):5580-5590. doi: 10.1016/j.vaccine.2018.07.056. Epub 2018 Aug 3.
7
There Is Always Another Way! Cytomegalovirus' Multifaceted Dissemination Schemes.
Viruses. 2018 Jul 20;10(7):383. doi: 10.3390/v10070383.
8
Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants.
Pediatr Infect Dis J. 2018 Jul;37(7):627-631. doi: 10.1097/INF.0000000000001877.
9
HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. doi: 10.1073/pnas.1800177115. Epub 2018 Apr 30.
10
Vaccination against the human cytomegalovirus.
Vaccine. 2019 Nov 28;37(50):7437-7442. doi: 10.1016/j.vaccine.2018.02.089. Epub 2018 Apr 3.
Zotero 插件